Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Pfizer/Warner-Lambert merger gets FTC nod

Published on .

The Federal Trade Commission on June 19 cleared the way for the $90 billion merger of Pfizer and Warner-Lambert Co. by accepting a consent agreement from the marketers. Under the agreement, the new company, to be called Pfizer, would end Warner-Lambert's co-marketing deal with Forest Laboratories on antidepressant Celexa (Pfizer markets the competing Zoloft); divest Pfizer's Rid head lice treatment business to Bayer Corp. (Warner-Lambert markets competitor Nix); divest all of Warner-Lambert's interests related to the Alzheimer's disease drug Cognex to First Horizon Pharmaceutical Corp. (Pfizer markets Alzheimer's treatment Aricept); and transfer and give up all of Pfizer's assets related to an anticancer drug in development to OSI Pharmaceuticals (Warner-Lambert has a similar product in the pipeline). The merger could lead to a shake-up in some agency assignments; the most prominent issue to be settled is what will happen to the new company's huge $700-plus million combined media budget.

Copyright June 2000, Crain Communications Inc.

In this article:
Most Popular